A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis

J. Koo, B. Abrams, G. Albrecht, P. Altmeyer, F. A. Bahmer, S. Belaich, J. Berth-Jones, J. R. Bjerke, J. D. Bos, L. Braathen, G. Burg, D. Burrows, A. Claudy, L. A. Drake, L. Dubertret, R. Engst, M. I. Ettelt, E. Frenk, P. J. Frosch, J. GanslandtM. Goos, R. A.C. Graham-Brown, J. J. Guilhou, U. F. Haustein, S. Helland, K. Hutchinson, H. Jacobi, E. G. Jung, S. Kang, P. Kind, J. Knop, N. J. Lowe, T. Luger, G. Mahrle, R. Marks, H. Meffert, J. Meyer, N. J. Mørk, U. Mrowietz, H. A.M. Neumann, E. A. Olsen, S. Rogers, T. Ruzicka, A. G. Schmidt, E. Schöpf, J. L. Shupack, T. M. Starink, D. Tio, W. A. Van Vloten, B. J. Vermeer, U. Wollina

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis'. Together they form a unique fingerprint.

Medicine & Life Sciences